Roche’s Ariosa Diagnostics has announced CE Mark approval for its Forte software, which will support continued expansion of the firm’s Harmony prenatal test in Europe and worldwide.

Forte software is used for analysis of cell-free DNA (cfDNA) isolated from plasma of a pregnant woman, in a bid to evaluate the risk of foetal chromosome 21, 18, and 13 trisomy, as well as foetal chromosome X and Y aneuploidy and foetal sex.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Combined with other clinical indicators and risk factors, the software is capable of providing a more accurate assessment of foetal chromosome conditions than other statistical methods.

"Combined with other clinical indicators and risk factors, the software is capable of providing a more accurate assessment of foetal chromosome conditions than other statistical methods."

Ariosa chief operating officer Dave Mullarkey said: "Forte software is a cornerstone of the Harmony prenatal test, which has been one of the most trusted brands in NIPT among patients and OB/GYNs to determine the risk of trisomies in more than 500,000 patients in the world.

"Achieving this regulatory milestone validates our efforts and allows Ariosa to partner with labs throughout Europe and license the Forte software required for technology transfers."

See Also:

The company intends to reside the software on a server at licensed labs to enable processing of patient data in the country of testing.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In a separate development, the company also granted licenses to laboratories to develop, validate and conduct non-invasive prenatal testing (NIPT) using its Harmony prenatal test technology in their own labs.

Features of the Harmony prenatal test technology include rapid turnaround time, foetal fraction measurement and reporting, scalability, as well as individualised patient risk score.

Ariosa Diagnostics CEO Ken Song said: "They represent a significant step in reaching our goal to offer the broadest access to the world’s leading and most validated NIPT to pregnant women worldwide."